Kim A Margolin

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)

P. Ascierto, J. Larkin, M. Atkins, 2022, Journal for ImmunoTherapy of Cancer.

State of the science 60th anniversary review

V. Sondak, M. Sabel, A. Daud, 2008, Cancer.

Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

H. Lenz, G. Schwartz, A. Bullock, 2023, Journal of Clinical Oncology.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

D. Schadendorf, P. Ascierto, R. Dummer, 2017, European journal of cancer.